GAMMA Investing LLC Has $888,000 Position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA)

GAMMA Investing LLC increased its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 1,509.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,762 shares of the company's stock after acquiring an additional 57,925 shares during the quarter. GAMMA Investing LLC's holdings in Centessa Pharmaceuticals were worth $888,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC raised its holdings in Centessa Pharmaceuticals by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 57,257 shares of the company's stock worth $959,000 after buying an additional 660 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $31,000. Barclays PLC raised its holdings in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares during the period. Franklin Resources Inc. raised its holdings in Centessa Pharmaceuticals by 0.3% during the 4th quarter. Franklin Resources Inc. now owns 2,308,546 shares of the company's stock worth $38,668,000 after buying an additional 6,000 shares during the period. Finally, Squarepoint Ops LLC raised its holdings in shares of Centessa Pharmaceuticals by 33.2% in the fourth quarter. Squarepoint Ops LLC now owns 26,806 shares of the company's stock valued at $449,000 after purchasing an additional 6,685 shares during the last quarter. Institutional investors own 82.01% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Needham & Company LLC assumed coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, May 28th. They issued a "buy" rating and a $35.00 price objective on the stock. Piper Sandler began coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price objective for the company. Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Oppenheimer initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, May 8th. They set an "outperform" rating and a $6.00 price objective for the company. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $27.89.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock traded up $0.08 during trading on Wednesday, reaching $12.68. The company's stock had a trading volume of 1,381,557 shares, compared to its average volume of 713,894. The business's 50-day moving average price is $12.63 and its 200-day moving average price is $14.94. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $8.46 and a 52 week high of $19.09. The company has a current ratio of 14.37, a quick ratio of 14.37 and a debt-to-equity ratio of 0.28.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.15. On average, research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, Director Arjun Goyal acquired 417,646 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was acquired at an average cost of $12.73 per share, for a total transaction of $5,316,633.58. Following the transaction, the director now directly owns 462,585 shares in the company, valued at $5,888,707.05. This represents a 929.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $16.69, for a total value of $917,950.00. Following the transaction, the chief executive officer now directly owns 276,017 shares of the company's stock, valued at approximately $4,606,723.73. The trade was a 16.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold 162,398 shares of company stock valued at $2,332,552 over the last quarter. 7.09% of the stock is owned by company insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.